See What HealthDay Can Do For You
Contact Us

Metabolite-Based Test May Detect Early Pancreatic Cancer

'Metabolomic analysis' of patients' blood shows high sensitivity and specificity

Metabolite-Based Test May Detect Early Pancreatic Cancer

FRIDAY, March 29 (HealthDay News) -- A test that measures four serum metabolites can accurately distinguish patients with pancreatic cancer from healthy people and patients with pancreatitis, according to a study published online March 29 in Cancer Epidemiology, Biomarkers & Prevention.

Takashi Kobayashi, M.D., Ph.D., from the Kobe University Graduate School of Medicine in Japan, and colleagues used gas chromatography-mass spectrometry to identify serum metabolites present in 43 patients with pancreatic cancer and 42 healthy volunteers.

The researchers found that a diagnostic model using four metabolites had a sensitivity of 86.0 percent and a specificity of 88.1 percent. Applying the model to an independent group of 42 patients with pancreatic cancer, 23 patients with chronic pancreatitis, and 41 healthy volunteers gave a sensitivity of 71.4 percent and a specificity of 78.1 percent. Compared with conventional tumor markers, the model had a higher sensitivity (77.8 percent) for resectable pancreatic cancer and a lower false positive rate (17.4 percent) for chronic pancreatitis.

"Our model possessed higher accuracy than conventional tumor markers at detecting the resectable patients with pancreatic cancer in [a] cohort including patients with chronic pancreatitis," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.